ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,180.48
-0.01%
Dow Jones
38,850.36
0.00%
US Dollar vs MXN
16.93437
0.29%
Brent Oil
83.065
-0.49%
Bitcoin
63,076.71
-0.14%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Iterum Therapeutics PLC (ITRM)

  7. Iterum Therapeutics PLC (ITRM) Noticias

ITRM

Iterum Therapeutics (ITRM)

Iterum Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ITRM
FechaHoraFuenteTítuloSímboloCompañía
06/05/202407:00GlobeNewswire Inc.Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:ITRMIterum Therapeutics PLC
29/04/202407:00GlobeNewswire Inc.Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
28/03/202406:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ITRMIterum Therapeutics PLC
28/03/202406:00GlobeNewswire Inc.Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
21/03/202415:30GlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:ITRMIterum Therapeutics PLC
15/03/202407:00GlobeNewswire Inc.Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatNASDAQ:ITRMIterum Therapeutics PLC
06/03/202407:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
06/03/202407:00GlobeNewswire Inc.Iterum Therapeutics Provides Business UpdateNASDAQ:ITRMIterum Therapeutics PLC
30/01/202406:00PR Newswire (US)Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
14/12/202306:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
14/12/202306:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
04/12/202316:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
04/12/202316:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITRMIterum Therapeutics PLC
04/12/202307:00GlobeNewswire Inc.Iterum Therapeutics Regains Compliance with Nasdaq Bid Price RuleNASDAQ:ITRMIterum Therapeutics PLC
07/11/202307:30GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:ITRMIterum Therapeutics PLC
24/10/202307:00GlobeNewswire Inc.Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
12/10/202308:15GlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2023NASDAQ:ITRMIterum Therapeutics PLC
11/08/202306:00GlobeNewswire Inc.Iterum Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
04/08/202316:00GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023NASDAQ:ITRMIterum Therapeutics PLC
15/06/202316:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ITRMIterum Therapeutics PLC
12/06/202317:23GlobeNewswire Inc.Iterum Therapeutics to Present Data at ASM Microbe 2023NASDAQ:ITRMIterum Therapeutics PLC
12/06/202315:45Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ITRMIterum Therapeutics PLC
05/06/202307:00Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ITRMIterum Therapeutics PLC
02/06/202315:13Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ITRMIterum Therapeutics PLC
12/05/202306:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ITRMIterum Therapeutics PLC
12/05/202306:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITRMIterum Therapeutics PLC
12/05/202306:00GlobeNewswire Inc.Iterum Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
20/04/202316:00GlobeNewswire Inc.Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration TrialsNASDAQ:ITRMIterum Therapeutics PLC
13/04/202315:16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ITRMIterum Therapeutics PLC
07/04/202311:15Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ITRMIterum Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ITRM

Su Consulta Reciente

AMEX
XLV
Health Care Select Sector
COIN
ETHUSD
Ethereum
USOTC
RHHBY
Roche (QX)
FX
USDMXN
US Dollar vs MXN
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
CCOM
SILVER
SILVER
FX
EURMXN
Euro vs MXN
NYSE
BAC
Bank of America
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
CVX
Chevron
USOTC
ADDYY
Adidas (QX)
NYSE
MCD
McDonalds
NYSE
MRK
Merck
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados